In a bold move, President Trump calls for pharmaceutical companies to justify the success of their Covid drugs amid a leadership crisis at the CDC. As the FDA tightens vaccine eligibility, tensions rise over vaccine efficacy and public health transparency.
Eli Lilly's new obesity pill, orforglipron, faces tough competition but could disrupt the weight loss market. Despite underwhelming trial results, analysts see potential for success due to manufacturing advantages and pricing strategies.
In a surprising turn, President Trump has retracted his plans for exorbitant tariffs on pharmaceuticals and semiconductors from the EU, capping them at 15%. This agreement, reached after intense negotiations, aims to stabilize trade relations and reduce costs for consumers and businesses.
Eli Lilly announces a dramatic price increase for its diabetes medication Mounjaro in the UK, raising the monthly cost from £122 to £330. This change affects private buyers but not NHS prescriptions. Learn more about the implications!
Discover the key elements of President Trump's new trade deal with the EU, including significant changes to tariffs on cars, pharmaceuticals, and more. Find out how this will affect trade relations and investments!
The White House unveils a $550 billion investment agreement with Japan, promising strategic investments in key sectors. But experts raise doubts about its feasibility amidst ongoing tariff controversies.
As Trump meets EU leaders in Scotland, intense negotiations are underway to prevent a costly trade war. With key issues at stake and heavy security, will a new trade deal emerge?
Isomorphic Labs, leveraging AI breakthroughs from DeepMind, is on the brink of human clinical trials for cancer drugs. With major pharma partnerships, the future of drug design looks promising!
In a surprising turn, Anne Wojcicki's nonprofit, TTAM Research Institute, has acquired 23andMe for $305 million after its bankruptcy. This acquisition addresses concerns about genetic data privacy while aiming to uphold the company's mission.
Anne Wojcicki's nonprofit has won the bid to buy 23andMe, raising critical questions about the future of genetic data privacy. Experts warn that sensitive DNA information could be at risk.
